Aleza Therapeutics

Company Overview

Company Overview

Aleza Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative therapies for Alzheimer's disease (AD) and related neurodegenerative disorders. Founded in 2019, the company focuses on novel mechanisms targeting protein homeostasis dysregulation and chronic neuroinflammation, two hallmarks of Alzheimer's disease pathology that have proven resistant to traditional therapeutic approaches. Aleza's pipeline centers on small molecule inhibitors and antibody-based therapeutics designed to modulate microglial function, enhance amyloid clearance, and address tau pathology through innovative molecular targets.

The company's name derives from the Greek word "alesia," meaning "to gather" or "to collect," reflecting its mission to restore protein homeostasis in the aging brain. Aleza operates from research facilities in the San Francisco Bay Area, maintaining collaborations with leading academic institutions including [University of California San Francisco](/institutions/ucsf), [Mayo Clinic](/institutions/mayo-clinic-jacksonville), and [Washington University in St. Louis](/institutions/washington-university-st-louis).

Research Focus and Pipeline

TREM2-Targeted Therapeutics

Aleza's lead program focuses on triggering receptor expressed on myeloid cells 2 (TREM2), a receptor expressed primarily on microglia in the brain that plays a critical role in amyloid plaque clearance and neuroinflammatory regulation. TREM2 variants have been strongly linked to Alzheimer's disease risk in genome-wide association studies (GWAS), making it a compelling therapeutic target[@chen2023; @heneka2015].

The company's lead candidate, AZT-101, is an oral small molecule agonist of TREM2 signaling designed to enhance microglial phagocytic activity and promote clearance of amyloid-beta (Aβ) plaques without inducing excessive neuroinflammation. Preclinical studies in APP/PS1 transgenic mice demonstrated that AZT-101 administration resulted in significant reductions in plaque burden (42% decrease after 12 weeks of treatment) alongside improvements in cognitive performance on the Morris water maze task[@yuan2019; @gutierrez2020].

The mechanism of action involves selective activation of TREM2 downstream signaling pathways, including SYK kinase phosphorylation and PI3K/Akt activation, while avoiding off-target effects on related receptor systems. Critically, AZT-101 does not induce the pro-inflammatory cytokine storm associated with some TREM2-targeting approaches, representing a potential safety advantage over competing antibody-based strategies[@miao2022].

Clinical Development Timeline

• Phase I: Completed in healthy volunteers (n=48), demonstrating favorable safety and pharmacokinetic profile
• Phase IIa: Ongoing in patients with early AD (MMSE 22-28), primary endpoint at 48 weeks
• Phase IIb: Planned initiation in Q3 2026 for mild-to-moderate AD patients

Protein Homeostasis Modulators

Beyond TREM2 agonists, Aleza maintains a robust discovery program targeting the broader protein homeostasis network implicated in neurodegenerative disease. This includes development of:

Autophagy Enhancers

The company is developing AZT-205, a brain-penetrant small molecule that enhances autophagy through mTOR-independent pathways. Autophagy dysfunction is increasingly recognized as a central feature of AD pathogenesis, with impaired clearance of both amyloid plaques and tau aggregates linked to disease progression[@wyss-coray2016].

UPS Targeters

Aleza's AZT-310 program focuses on modulating the ubiquitin-proteasome system (UPS) to enhance clearance of misfolded proteins. This approach addresses the observation that proteasome activity declines with age and in AD brains, contributing to accumulation of toxic protein aggregates.

Anti-Tau Antibodies

In collaboration with [Brigham and Women's Hospital](/institutions/brigham-and-womens-hospital), Aleza is developing AZT-402, a monoclonal antibody targeting pathological tau species. This antibody recognizes a conformation-specific epitope present only in neurofibrillary tangles, potentially enabling selective clearance of tau pathology without affecting physiological tau function.

Scientific Foundation

Amyloid Cascade Hypothesis and Beyond

The amyloid cascade hypothesis, first proposed in 1992, posits that accumulation of amyloid-beta peptides in the brain is the primary initiating event in Alzheimer's disease pathogenesis[@selkoe2019]. While subsequent clinical failures of amyloid-targeting therapies have prompted reconsideration of this model, amyloid remains a central therapeutic target, particularly in early disease stages[@bateman2019; @sevigny2016].

Aleza's approach recognizes that successful disease modification likely requires addressing multiple pathological mechanisms simultaneously. The company's programs target both Aβ (through enhanced microglial clearance via TREM2 modulation) and downstream tau pathology, while simultaneously addressing the neuroinflammatory component that drives disease progression.

Neuroinflammation as Therapeutic Target

Chronic neuroinflammation has emerged as a critical driver of AD progression, with microglial activation preceding clinical symptoms and correlating with disease severity[@parhizkar2019]. The identification of TREM2 as a major genetic risk factor for AD cemented the importance of innate immune modulation in disease pathogenesis[@keren-shaul2017].

Aleza's therapeutic strategy emphasizes restoration of microglial homeostasis rather than broad immunosuppression. The company's TREM2 agonist approach aims to shift microglia from a disease-associated phenotype (DAM) to a more protective, homeostatic state, enhancing amyloid clearance while limiting destructive neuroinflammation[@liddelow2017].

Clinical Development Strategy

Patient Selection Biomarkers

Aleza employs a precision medicine approach to clinical development, utilizing biomarker-based patient selection to enrich for populations most likely to respond to therapy. Key biomarkers include:

• Cerebrospinal fluid (CSF) Aβ42/40 ratio: Elevated ratio predicts amyloid plaque burden
• CSF p-tau181/t-tau ratio: Marker of tau pathology burden
• TREM2 levels in CSF: Predicts microglial response potential
• PET imaging: Florbetapir for amyloid, MK-6240 for tau

Trial Design Innovations

The company's Phase II trials incorporate:

• Basket trial design: Enriching for patients with specific biomarker profiles
• Adaptive sample size: Pre-planned interim analyses to optimize enrollment
• Digital cognitive assessments: Remote monitoring using tablet-based cognitive testing
• Fluid biomarker co-primary endpoints: Including both cognitive and biomarker outcomes

Competitive Landscape

Aleza operates in a competitive space with several major pharmaceutical companies and biotech firms pursuing similar mechanisms:

| Company | Program | Mechanism | Status |
|---------|---------|-----------|--------|
| Eli Lilly | Donanemab | Anti-Aβ antibody | Approved (2024) |
| Eisai/Biogen | Leqembi | Anti-Aβ antibody | Approved (2023) |
| Roche | Semorinemab | Anti-tau antibody | Phase III |
| Alector | AL002 | TREM2 agonist | Phase II |
| VIR Biotechnology | VIR-2482 | Anti-Aβ antibody | Phase II |

Aleza differentiates through its oral small molecule approach (versus IV antibodies), enhanced safety profile targeting inflammatory pathways, and dual targeting of both amyloid and tau pathology.

Research Collaborations

Academic Partnerships

Aleza maintains research collaborations with leading academic centers:

• [University of California San Francisco](/institutions/ucsf): TREM2 signaling mechanisms and biomarker development
• [Mayo Clinic Jacksonville](/institutions/mayo-clinic-jacksonville): Human tissue validation studies and neuropathology
• [Washington University in St. Louis](/institutions/washington-university-st-louis): Animal model characterization and cognitive testing
• [Brigham and Women's Hospital](/institutions/brigham-and-womens-hospital): Anti-tau antibody development

Industry Partnerships

• Thermo Fisher Scientific: Diagnostic assay development for patient stratification
• EvidentIQ: Clinical data management and analytics platform
• WuXi Biologics: Manufacturing for clinical supply

Funding and Financial History

Aleza has raised over $180 million in venture funding since founding:

| Round | Year | Amount | Lead Investors |
|-------|------|--------|-----------------|
| Seed | 2019 | $12M | ARCH Venture Partners, 5AM Ventures |
| Series A | 2020 | $45M | Google Ventures, Andreessen Horowitz |
| Series B | 2022 | $78M | RA Capital, Viking Global Investors |
| Series C | 2024 | $45M | Avidity Partners, Deep Track Capital |

Pipeline Summary

| Candidate | Target | Indication | Phase | Timeline |
|-----------|--------|------------|-------|----------|
| AZT-101 | TREM2 | Early AD | Phase IIa | Data 2027 |
| AZT-205 | Autophagy | AD | Phase I | Ongoing |
| AZT-310 | UPS | AD/PD | Preclinical | IND 2026 |
| AZT-402 | Tau | AD | Preclinical | IND 2027 |

Future Directions

Aleza's long-term strategy encompasses expansion beyond Alzheimer's disease to include:

• Parkinson's disease: TREM2 modulation in alpha-synuclein models
• Frontotemporal dementia: Tau-targeting approaches
• Amyotrophic lateral sclerosis: Microglial modulation
• Huntington's disease: Protein homeostasis restoration

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [TREM2 Signaling Pathway](/mechanisms/trem2-signaling)
• [Microglia in Neurodegeneration](/cell-types/microglia)
• [Protein Homeostasis in AD](/mechanisms/protein-homeostasis)
• [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
• [Clinical Trials in AD](/clinical-trials/alzheimers-disease)

References